Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Total Current Liabilities (2024 - 2025)

Evommune (EVMN) has disclosed Total Current Liabilities for 2 consecutive years, with $17.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 36.0% to $17.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.9 million, a 36.0% decrease, with the full-year FY2025 number at $17.9 million, down 36.0% from a year prior.
  • Total Current Liabilities was $17.9 million for Q4 2025 at Evommune, up from $10.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $28.0 million in Q4 2024 to a low of $10.4 million in Q3 2025.